Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs

Journal of Infectious Diseases

Volumn 187, Issue 4, 2003, Pages 542-549

  Bourne, Nigel ^a,c   Bravo, Fernando J ^a   Francotte, Myriam ^b   Bernstein, David I ^a   Myers, Martin G ^a,c   Slaoui, Moncef ^b   Stanberry, Lawrence R ^a,c  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; GLYCOPROTEIN D; IMMUNOLOGICAL ADJUVANT; PHOSPHORYL LIPID A; SUBUNIT VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; FEMALE; GENITAL HERPES; GUINEA PIG; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; IMMUNIZATION; NONHUMAN; PRIMARY INFECTION; PRIORITY JOURNAL; RECURRENT DISEASE; SEROLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; GUINEA PIGS; HERPES GENITALIS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; RECURRENCE; VACCINATION; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

EID: 0037442496     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/374002     Document Type: Article

References (41)

1. Ashley RL, Wald A. Genital herpes: review of the epidemic and potential use of type-specific serology. Clin Microbiol Rev 1999; 12:1-8.
2. Stanberry L, Cunningham A, Mertz G, et al. New developments in the epidemiology, natural history, and management of genital herpes. Antiviral Res 1999; 42:1-14.
3. Fleming DT, McQuillen GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997; 337:1105-11.
4. Ribes JA, Steele AD, Seabolt JP, Baker DJ. Six-year study of the incidence of herpes in genital and nongenital cultures in a central Kentucky medical center patient population. J Clin Microbiol 2001; 39:3321-5.
5. Tayal SC, Pattman RS. High prevalence of herpes simplex virus type 1 in female anogenital herpes simplex in Newcastle-upon-Tyne 1983-92. Int J STD AIDS 1994; 5:359-61.
6. Thompson C. Genital herpes simplex typing in genitourinary medicine: 1995-1999. Int J STD AIDS 2000; 11:501-2.
7. Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet 2001; 357:1513-8.
8. Patel R, Boseli F, Cairo I, Barnett G, Price M, Wulf HC. Patients' perspectives on the burden of recurrent genital herpes. Int J STD AIDS 2001; 12:640-5.
9. Mindel A. Psychological and psychosexual implications of herpes simplex virus infections. Scand J Infect Dis Suppl 1996; 100:27-32.
10. Perez G, Skurnick JH, Denny TN, et al. Herpes simplex type II and Mycoplasma genitalium as risk factors for heterosexual HIV transmission: report from the heterosexual HIV transmission study. Int J Infect Dis 1998; 3:5-11.
11. Chen CY, Ballard RC, Beck-Sague CM, et al. Human immunodeficiency virus infection and genital ulcer disease in South Africa: the herpetic connection. Sex Transm Dis 2000; 27:21-9.
12. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992; 116:197-202.
13. Brown ZA, Selkes S, Zeh J, et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997; 337:509-15.
14. Tao G, Kassler WJ, Rein DB. Medical care expenditures for genital herpes in the United States. Sex Transm Dis 2000; 27:32-8.
15. Bernstein DI, Stanberry LR. Herpes simplex virus vaccines. Vaccine 1999; 17:1681-9.
16. Langenberg AGM, Burke RL, Adair SF, et al. A recombinant glycoprotein vaccine for herpes simplex type 2: safety and efficacy. Ann Intern Med 1995; 122:889-98.
17. Corey L, Langenberg AGM, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection - two randomized controlled trials. JAMA 1999; 282:331-40.
18. Thoelen S, De Clercq N, Tornieporth N. A prophylactic hepatitis vaccine with a novel adjuvant system. Vaccine 2001; 19:2400-3.
19. Bernstein DI. Efficacy of a prophylactic herpes simplex type 2 glycoprotein D vaccine: results of two clinical efficacy trials. SmithKline Beecham Herpes Vaccine Efficacy Study Group. Pediatr Res 2001; 49(Suppl):256a.
20. Stanberry LR, Kern ER, Abbott TM, Overall JC Jr. Genital herpes in guinea pigs: pathogenesis of the primary infection and the description of recurrent disease. J Infect Dis 1982; 146:397-404.
21. Stanberry LR, Kern ER, Richards JT, Overall JC Jr. Recurrent genital herpes simplex virus infections in guinea pigs. Intervirology 1985; 24:226-31.
22. Bourne N, Stanberry LR. Animal models of herpesvirus genital infection: guinea pig. In: Zak O, Sande MA, eds. Handbook of animal models of infection. London: Academic Press, 1999:907-10.
23. Reeves WC, Corey L, Adams HG, Vontver LA, Holmes KK. Risk of recurrence after first episodes of genital herpes: relation to HSV type and antibody response. N Engl J Med 1981; 305:315-9.
24. Bourne N, Stanberry LR, Bernstein DI, Lew D. DNA immunization against experimental genital herpes simplex virus infection. J Infect Dis 1996; 173:800-7.
25. Stanberry LR, Kit S, Myers MG. Thymidine kinase-deficient herpes simplex virus type 2 genital infection in guinea pigs. J Virol 1985; 55:322-8.
26. Eisenberg RJ, Ponce de Leon M, Cohen GH. Comparative structural analysis of glycoprotein gD of herpes simplex virus types 1 and 2. J Virol 1980; 35:428-35.
27. Watson RJ. DNA sequence of the herpes simplex virus type 2 glycoprotein D gene. Gene 1983; 26:307-12.
28. Stanberry LR, Bernstein DI, Kit S, Myers MG. Genital reinfection after recovery from initial genital infection with herpes simplex virus type 2 in guinea pigs. J Infect Dis 1986; 153:1055-61.
29. Stanberry LR, Myers MG, Stephanopoulos DE, Burke RL. Preinfection prophylaxis with herpes simplex virus glycoprotein immunogens: factors influencing efficacy. J Gen Virol 1989; 70:3177-85.
30. Bournsell MEG, Entwhistle C, Blakeley D, et al. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis 1997; 175:16-25.
31. Da Costa XJ, Bourne N, Stanberry LR, Knipe DM. Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease. Virology 1997; 232:1-12.
32. Spector FC, Kern ER, Palmer J, et al. Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs. J Infect Dis 1998; 177:1143-54.
33. Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. In: Powell MF, Newman MJ, eds. Vaccine design: the subunit and adjuvant approach. New York: Plenum Press 1995:495-524.
34. Moore A, McCarthy L, Mills KH. The adjuvant combination monophosphoryl lipid A and QS21 switches T-cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine 1999; 17:2517-27.
35. Singh M, O'Hagan D. Advances in vaccine adjuvants. Nat Biotechnol 1999; 17:1075-81.
36. Milligan GN, Bernstein DI, Bourne N. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with HSV type 2. J Immunol 1998; 160:6093-100.
37. Deshpande SP, Kumaraguru U, Rouse BT. Why do we lack an effective vaccine against herpes simplex virus infections? Microbes Infect 2000; 2:973-8.
38. Cunningham AL, Mikloska Z. The holy grail: immune control of human herpes simplex virus infection and disease. Herpes 2001; 8(Suppl 1):6A-10.
39. Rooney JF, Felser JM, Ostrove JM, Straus SE. Acquisition of genital herpes from an asymptomatic sexual partner. N Engl J Med 1986; 314:1561-4.
40. Mertz GJ, Coombs RW, Ashley R, et al. Transmission of genital herpes in couples with one symptomatic and one asymptomatic partner: a prospective study. J Infect Dis 1988; 157:1169-77.
41. Garnett GP. Herpes simplex virus type 2 epidemiology in the United States and the potential impact of a vaccine. Int J STD AIDS 2001; 12(Suppl 2):149.